MOMA Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
80 Guest St Fl 5, Brighton, Massachusett...Phone Number
(617) 936-0384Website
www.momatx.comRevenue
$18.2 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About MOMA Therapeutics
MOMA Therapeutics is focused on discovering the next generation of precision medicines by targeting the molecular machines that are fundamental to human disease. The company emphasizes the need for drug discovery to adapt to the best targets available. With a strong team and significant investment backing, MOMA is dedicated to addressing urgent patient needs through innovative science. Their approach involves a comprehensive pipeline aimed at advancing therapeutic solutions.Explore more
MOMA Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MOMA Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when MOMA Therapeutics launches new products
Check out if MOMA Therapeutics is spiking on competitors!
Check if MOMA Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once MOMA Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
MOMA Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on MOMA Therapeutics recently announced quarterly report
Click to see if MOMA Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at MOMA Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to MOMA Therapeutics
Compare insights from companies similar to MOMA Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$20M
51-200
Public
$496M
2018
HB
Harold BernsteinPresident, Research & Chief Medical Officer, Development
Company Profile Activity
Activity Insights
MOMA Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MOMA Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MOMA Therapeutics.
MOMA Therapeutics financials insights
Gather financial insights about MOMA Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$86M
2022
Series B
$150M
MOMA Therapeutics Tech Stack
A closer look at the technologies used by MOMA Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
MOMA Therapeutics News & Media
MOMA Therapeutics to Present Multiple Posters at the American Association for Cancer Research Annual Meeting 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced three poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting, being held April 25 – 30, 2025 in Chicago, IL. AACR poster presentation details are below: MOMA-313 is a potent and selective inhibitor of the Polθ DNA helicase domain for the treatment of HR-deficient tumors SesMOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Directors and Expands Management Team
CAMBRIDGE, Mass.--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics today announced the appointment of Susan Pandya, M.D., as an independent member of the company’s board of directors. “We are thrilled to welcome Susan during this exciting time as we advance all three of our lead assets toward responses in the clinic,” said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA. “Susan’s depthMOMA Therapeutics Provides Corporate Update and Announces Exclusive License Agreement for Selective PARP1 Inhibitor
CAMBRIDGE, Mass.--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective PARP1 (poly ADP-ribose polymerase) inhibitor, now known as MOMA-989. The company also provided an update on the clinical progress of Polθ inhibitor MOMA-313 and outlined the clinical path for Werner inhibitor MOMA-341. “The addition of this selective PARP1 inhibitorMOMA Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--MOMA Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that company management will participate in two upcoming investor conferences: Guggenheim Global Healthcare Conference 2024: Asit Parikh, M.D., Ph.D., MOMA Therapeutics CEO, will participate in the Oncology Platform Innovators panel on Tuesday, November 12 from 11:00 – 11:50 a.m. ET in Boston, MA. Piper Sand
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding MOMA Therapeutics
Sign Up For FreeTo access detailed company insights
MOMA Therapeutics is focused on discovering the next generation of precision medicines by targeting the molecular machines that are fundamental to human disease. The company emphasizes the need for drug discovery to adapt to the best targets available. With a strong team and significant investment backing, MOMA is dedicated to addressing urgent pat... Read More
